Who is sponsoring NCT05394714?

NCT05394714 is sponsored by Medigen Biotechnology Corporation.

What drugs are being tested in NCT05394714?

Interventions in NCT05394714: Magicell-NK contains NK cells suspended in 100 mL normal saline.

What condition does NCT05394714 study?

NCT05394714 studies Colon Cancer Stage I.

Is NCT05394714 still recruiting?

NCT05394714 is currently recruiting now. Last updated 23 September 2025.

Last reviewed 2025-09-23 · How we verify

NCT05394714

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I, Autologous ex Vivo Expanded and Activated NK Cell, Magicell-NK, Infusion for Colon Cancer Post Resection Study

Recruiting now Phase 1 Last updated 23 September 2025

What this trial tests

Phase 1 trial testing Magicell-NK contains NK cells suspended in 100 mL normal saline in Colon Cancer Stage I in 18 participants. Currently enrolling.

Timeline

10 March 2022

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	Medigen Biotechnology Corporation
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	10 March 2022
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	1 location across Taiwan

Drugs / interventions tested

Magicell-NK contains NK cells suspended in 100 mL normal saline — full drug profile →

Conditions studied

Colon Cancer Stage I — all drugs for Colon Cancer Stage I →

Sponsor

Medigen Biotechnology Corporation — full company profile →

Who can join

20 and older, any sex, with Colon Cancer Stage I. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase I, open-label study to explore the safety profile and to find the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of Magicell-NK in subjects diagnosed with stage I or stage IIa colon cancer post resection from a single site in Taiwan. During this study, 3 dose levels of Magicell-NK will be tested with a 3+3 design to determine the MTD/MFD: Cohort 1, low dose (2×10\^8 cells), Cohort 2, middle dose (6×10\^8 cells), and Cohort 3, high dose (12\~18 ×10\^8 cells).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

NK cells and solid tumors: therapeutic potential and persisting obstacles.
Tong L, Jiménez-Cortegana C, Tay AHM, Wickström S, et al · · 2022 · cited 134× · PMID 36319998 · DOI 10.1186/s12943-022-01672-z
Redefining cancer care: harnessing circulating tumor cells' potential for improved diagnosis and prognosis.
Janjua D, Chaudhary A, Joshi U, Tripathi T, et al · · 2025 · cited 4× · PMID 40676582 · DOI 10.1186/s12935-025-03883-y

Verify or expand the search:

Other Medigen Biotechnology Corporation trials

Trials by the same sponsor.

NCT06730009 — Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05394714 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medigen Biotechnology Corporation
Last refreshed: 23 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05394714.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing